Skip to Main Content

Hospitals are thrilled that they’re now able to offer cancer patients pioneering CAR-T treatments, but they’re also running into the omnipresent problem surrounding these and other next-generation therapies: cost.

In a speech Wednesday at the Personalized Medicine Conference, Dr. Betsy Nabel, the president of Brigham and Women’s Hospital, said her hospital and others in the Partners HealthCare system are not being reimbursed fully when they treat patients with CAR-T therapies, leaving the providers to subsidize the treatments.


“The finances are not sustainable,” she said at the conference, which was being held at Harvard Medical School.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • I believe that process cost universities doing the research aproximately 20,000 per patient to regrow the cells outside the body and so the rest of the 400,000 is likely for some patent holder. Therefore I think there’s going to be an industry of sending patients to China for this therapy where they not worried about US patents .

  • Thank you for keeping the public up to date on new research and treatments for cancer. My husband passed away recent look y from Sarcoma. No existing treatments could stop his disease and least of all alleviate his pain. I am still very upset at the Sarcoma center for their lack of communication into clinical trials and innovative therapies to offer patients. Keep up the good work.

Comments are closed.